|Awarded On||August 18, 2021|
|Title||Novel pharmacodynamic assay to predict response to CDK4/6 inhibitor therapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||University of Houston|
|Principal Investigator/Program Director||Madhukar Trivedi|
*Pending contract negotiation
Novel targeted therapies have provided advantage in extending survival in cancer patients. However, these therapies do not benefit all patients. They also have severe toxicities and high costs. Inappropriate selection of first- or second-line therapies can drastically limit the long-term survival especially in patients with metastatic disease. One such novel targeted therapy is the class of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i’s). Three agents (palbociclib, ribociclib, abemaciclib) are approved by the FDA in hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer. They improve survival when combined with standard endocrine ...